&bgr;-sulfonyl hydroxamic acids

Details &bgr;-sulfonyl hydroxamic acids &bgr;-sulfonyl hydroxamic acids

1999-07-26

2001-05-22

Higel, Floyd D. (Department: 1626)

Organic compounds -- part of the class 532-570 series

Organic compounds

Carboxylic acids and salts thereof

C548S319500, C562S581000, C562S621000

Reexamination Certificate

active

06235928

ABSTRACT:

FIELD OF THE INVENTION
The present invention relates to novel sulfonyl hydroxamic acids, to pharmaceutical compositions containing them, and to the method of using them. The compounds of the invention are inhibitors of matrix metalloproteinases involved in tissue degradation.
BACKGROUND OF THE INVENTION
Loss of connective tissue integrity occurs in many disease processes, including osteoarthritis, rheumatoid arthritis, septic arthritis, osteopenias such as osteoporosis, tumor metastasis (invasion and growth), periodontitis, gingivitis, corneal ulceration, dermal ulceration, gastric ulceration, inflammation, asthma and other diseases related to connective tissue degradation. Although there is a high incidence of these diseases in the developed world, there is no treatment that prevents the tissue damage that occurs. Considerable lines of scientific evidence indicate that uncontrolled connective matrix metalloproteinase (MMPs) activity is responsible for the damage, and as a consequence the inhibition of these enzymes has become the target for therapeutic intervention (see Matrisian, L. A, Bases, Vol. 14, pp 445-463 (1992); Emonard, H. et al., Cellular and molecular Biology, Vol. 36, pp 131-153 (1990); Docherty, A J. P. et al., Annals of the Rheumatic, Vol. 49, pp 469-479 (1990)).
Hydroxamic acid derivatives are a class of known therapeutically active MMPs inhibitors and there are numerous references in the art disclosing a variety of hydroxamic acid derivatives. For example, European Patent Publication 0,606,046 A1 discloses arylsulfonamido-substituted hydroxamic acids useful as matrix metalloproteinase inhibitors. International Publication Nos. WO 95/35275 and WO 95/35276 disclose sulfonamide hydroxamic acid and carboxylic acid derivatives useful as matrix metalloproteinases inhibitors. All these references relate to sulfonamide hydroxamic acids. The compounds of this invention are novel and distinct from all other sulfonamide hydroxamic acids in that the usual nitrogen atom is replaced by a carbon atom. The invention provides sulfonyl hydroxamic acid derivatives.
The compounds of the present invention inhibit various enzymes from the matrix metalloproteinase family, predominantly stromelysin and gelatinase, and hence are useful for the treatment of matrix metallo endoproteinase diseases such as osteoporosis, tumor metastasis (invasion and growth), periodontitis, gingivitis, corneal ulceration, dermal ulceration, gastric ulceration, inflammation, asthma, and other diseases related to connective tissue degradation.
INFORMATION DISCLOSURE
The following references disclose sulfonyl hydroxamic acid derivatives.
International Publication No. WO 95/09841 discloses hydroxamic acid compounds useful as inhibitors TNF and matrix metalloproteinases.
International Publication No. WO 93/20047 discloses hydroxamic acid compounds useful as inhibitors of tumour necrosis factor production and of matrix metalloproteinases.
International Publication No. WO 90/05719 discloses hydroxamic acid compounds useful in the management of diseases involving tissue degradation and/or the promotion of wound healing.
The hydroxamic acid compounds in the above identified references have an obligatory peptide backbone. The compounds of the present invention are distinct from the above noted references in that they do not have a peptide backbone.
The European Patent Application EP 0780 386 Al discloses matrix metalloproteinases inhibitors useful in the treatment of mammals having disease states alleviated by the inhibition of such matrix metalloproteinases.
International Publication No. WO 97/24117 discloses substituted aryl, heteroaryl, arylmethyl or heteroarylmethyl hydroxamic acid compounds especially useful for inhibiting the production or physiological effects of TNF in the treatment of a patient suffering from a disease state associated with a physiologically detrimental excess of tumor necrosis factor (TNF).
SUMMARY OF THE INVENTION
The present invention provides novel compounds of formula I
or pharmaceutical acceptable salts thereof wherein:
R
1
is
a) C
4-12
alkyl,
b) C
4-12
alkenyl,
c) C
4-12
alkynyl,
d) —(CH
2
)
h
—C
3-8
cycloalkyl,
e) —(CH
2
)
h
-aryl,
f) —(CH
2
)
h
-aryl substituted with C
1-4
alkyl, C
1-4
alkoxy, halo, —NO
2
, —CF
3
, —CN, or —N(C
1-4
alkyl)
2
,
g) —(CH
2
)
h
-het, or
h) —(CH
2
)
h
-het substituted with C
1-4
alkyl, or halo;
R
2
is
a) C
1-12
alkyl,
b) C
1-12
alkyl substituted with one to three halo, —CN, —NO
2
, —CF
3
, —N(R
3
)
2
, —SR
3
, or OH,
c) C
2-12
alkenyl,
d) C
2-12
alkenyl substituted with one to three halo, —CN, —NO
2
, or —CF
3
,
e) C
2-12
alkynyl,
f) C
2-12
alkynyl substituted with one to three halo, —CN, —NO
2
, or —CF
3
,
g) —(CH
2
)
h
—C
3-8
cycloalkyl,
h) —(CH
2
)
h
—C
3-8
cycloalkyl substituted with one to three C
1-4
alkyl, C
1-4
alkoxy, or halo,
i) —(CH
2
)
h
—C
3-8
cycloalkenyl,
j) —(CH
2
)
h
—C
3-8
cycloalkenyl substituted with one to three C
1-4
alkyl, C
1-4
alkoxy, or halo,
k) —(CH
2
)
h
-aryl,
l) —(CH
2
)
h
-aryl substituted with one to three C
1-4
alkyl, C
1-4
alkoxy, —CF
3
—OH, —NO
2
, —CN, —N(R
3
)
2
, —SR
3
,—SO
2
(C
1-4
alkoxy), —C(═O)R
3
, or —NC(═O)R
3
,
m) —(CH
2
)
h
-aryl substituted with one to five halo,
n) —(CH
2
)
h
-het,
o) —(CH
2
)
h
-het substituted with one to two C
1-4
alkyl, or halo,
p) —(CH
2
)
h
-Q,
q) —(CH
2
)
h
-Q substituted with one to three C
1-4
alkyl, C
1-4
alkoxy, halo, or phenyl,
r) —(CH
2
)
i
—X—R
4
, optionally the —(CH
2
)
i
- chain can be substituted with C
1-4
alkyl or phenyl, which in turn can be substituted with one to three halo or C
1-4
alkyl, or
s) —(CH
2
)
i
CHR
5
R
6
;
R
3
is
a) H,
b) C
1-4
alkyl,
c) —(CH
2
)
h
-phenyl, or
d) —(CH
2
)
h
-phenyl substituted with one to three C
1-4
alkyl, C
1-4
alkoxy, or halo;
X is
a) —O—,
b) —S(═O)
j
—,
c) —NR
7
—, —
d) —S(═O)
2
NR
8
—, or
e) —C(═O)—;
R
4
is
a) H,
b) C
1-4
alkyl,
c) —(CH
2
)
h
-phenyl,
d) —(CH
2
)
h
-phenyl substituted with one to three C
1-4
alkyl, C
1-4
alkoxy, halo, —NO
2
, or —CN, or
e) —(CH
2
)
h
-het;
R
5
is
a) C
1-4
alkyl, or
b) —C(═O)R
3
;
R
6
is
a) —C(═O)R, or
b) —(CH
2
)
h
C(═O)R
3
;
R
7
is
a) H,
b) C
1-4
alkyl,
c) —(CH
2
)
h
-phenyl,
d) —(CH
2
)
h
-phenyl substituted with one to three C
1-4
alkyl, C
1-4
alkoxy, or halo,
e) —C(═O)—R
3
,
f) —S(═O)
2
R
3
, or
g) —C(═O)OR
3
;
R
8
is
a) C
1-4
alkyl,
b) —(CH
2
)
h
-phenyl, or
c) —(CH
2
)
h
-phenyl substituted with one to three C
1-4
alkyl, C
1-4
alkoxy, or halo;
aryl is monocarbocyclic, or bicarbocyclic aromatic moiety; het is 5- to 10-membered unsaturated heterocyclic moiety having one to three atoms selected from the group consisting of oxygen, nitrogen, and sulfur; Q is 5- to 10-membered saturated heterocyclic moiety having one to two atoms selected from the group consisting of oxygen, nitrogen, and sulfur; h is 0, 1, 2, 3, 4, 5, or 6; i is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; and is 0, 1, or 2.
The compounds of the present invention inhibit various enzymes from the matrix metalloproteinase family, predominantly stromelysin and gelatinase, and hence are useful for the treatment of matrix metallo endoproteinase diseases
DETAILED DESCRIPTION OF THE INVENTION
For the purpose of the present invention, the carbon content of various hydrocarbon containing moieties is indicated by a prefix designating the minimum and maximum number of carbon atoms in the moiety, i.e., the prefix C
i-j
defines the number of carbon atoms present from the integer “i” to the integer “j”, inclusive. Thus, C
1-4
alkyl refers to alkyl of one to four carbon atoms, inclusive, or methyl, ethyl, propyl, butyl and isomeric forms thereof.
The terms “C
1-4
alkyl”, “C
4-8
alkyl”, “C
1-12
alkyl”, and “C
1-18
alkyl” refer to an alkyl group having one to four, four to eight, one to twelve, or one to eighteen carbon atoms respectively such as; for example, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl, tridecyl, tetradecyl and their isomeric forms thereof, preferably an alkyl group of R
1
havi

Affiliated with

Also associated with

Rating

&bgr;-sulfonyl hydroxamic acids does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with &bgr;-sulfonyl hydroxamic acids, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and &bgr;-sulfonyl hydroxamic acids will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2447978